Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases

Abstract

The present disclosure provides a crystal form comprising a compound of Formula (I) and fumaric acid, wherein the crystal form satisfies at least one of the following conditions: (1) a particle size D90 of the active pharmaceutical ingredient ranges from about 5 μm to about 60 μm; and (2) a particle size D50 of the active pharmaceutical ingredient does not exceed about 30 μm; a pharmaceutical composition containing the crystal form, and a method for treating coronavirus-induced diseases by using the crystal form. The crystal form of the present disclosure enables the pharmaceutical composition containing the crystal form to have advantages such as a higher dissolution rate, a higher dissolution, and the like.

Dependencies are inferred from the claim text.